据天眼查APP显示，贵州百灵企业集团制药股份有限公司成立于1999年03月25日，注册资本139759.84 万人民币。（数据宝） （原标题：ST百灵12月25日大宗交易成交213.20万元） ST百灵12月25日大宗交易平台出现一笔成交，成交量40.00万股，成交金额213.20万元，大宗交易成交 价为5.33元，相对今日收盘价溢价10.35%。该笔交易的买方营业部为长江证券股份有限公司武汉分公 司，卖方营业部为长江证券股份有限公司武汉友谊大道证券营业部。 证券时报•数据宝统计显示，ST百灵今日收盘价为4.83元，下跌4.92%，日换手率为0.39%，成交额为 2272.13万元，全天主力资金净流出118.53万元，近5日该股累计下跌12.66%，近5日资金合计净流出 205.54万元。 两融数据显示，该股最新融资余额为5.56亿元，近5日减少1282.78万元，降幅为2.26%。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 12月25日ST百灵大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当日 | | | | --- | --- | --- | --- | --- | --- ...

贵州百灵企业集团制药股份有限公司 股票交易异常波动公告 证券代码：002424 证券简称：ST 百灵 公告编号：2025-055 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 贵州百灵企业集团制药股份有限公司（以下简称"公司"）股票 （证券简称：ST 百灵，证券代码：002424）连续 3 个交易日（2025 年 12 月 23 日、2025 年 12 月 24 日、2025 年 12 月 25 日）日收盘价 格跌幅偏离值累计超过 12%，根据《深圳证券交易所交易规则》的有 关规定，该情形属于股票交易异常波动的情况。 二、公司关注及核实情况的说明 公司董事会确认，公司目前没有任何根据《深圳证券交易所股票 上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的 筹划、商谈、意向、协议等；董事会也未获悉本公司有根据《深圳证 券交易所股票上市规则》等有关规定应予以披露而未披露的、对本公 司股票及其衍生品种交易价格产生较大影响的信息；公司前期披露的 信息不存在需要更正、补充之处。 四、风险提示 1、经自查，公司不存在违反信息公平 ...

Core Viewpoint - The regulatory environment for listed companies in China has intensified in 2025, with over 80 companies facing penalties for information disclosure violations, reflecting a shift from lenient to strict enforcement by the China Securities Regulatory Commission (CSRC) [1][6] Group 1: Regulatory Actions - The CSRC has maintained a high-pressure stance on information disclosure violations, with penalties reaching up to 10 million yuan for companies and 500,000 yuan for responsible individuals, a significant increase from previous years [1][6] - Various types of violations have been identified, including failure to disclose periodic reports, financial fraud, and misuse of funds by actual controllers [1][6] Group 2: Financial Fraud Cases - Notable cases of financial fraud include: - Notai Bio, which inflated revenue by 30 million yuan through a closed-loop funding operation and faced a fine of 76.2 million yuan [2][8] - *ST Zitian, which reported inflated revenue of 2.499 billion yuan over two years, with 78.63% of its 2023 revenue being fictitious [2][8] - *ST Suwu, which failed to disclose its actual controller for several years and inflated revenue by 1.771 billion yuan while concealing 4.755 billion yuan in non-operating fund occupation [2][8] Group 3: Consequences of Violations - The implementation of a strict delisting mechanism has led to over 10 companies facing mandatory delisting due to severe violations, with *ST Yuancheng being the 13th company to face such consequences in 2025 [2][8] - The involvement of third-party entities in fraudulent activities has also been addressed, with penalties imposed on accomplices, such as the case of Nanjing Qingya Trading Co., which faced a fine of 7 million yuan and a 10-year market ban [2][8] Group 4: Shareholder Rights and Legal Actions - The regulatory framework now includes comprehensive accountability measures for not only the companies but also responsible individuals and intermediaries involved in fraudulent activities [4][11] - Shareholders affected by violations have successfully pursued legal actions, with several cases resulting in compensation for investors, highlighting the importance of active participation in seeking redress [4][11]

Core Viewpoint - Financial fraud has severely undermined the principles of fairness and transparency in the A-share market, harming the legitimate rights and interests of investors, with over 10 listed companies facing penalties and forced delisting since 2025, including five companies receiving fines exceeding 100 million RMB [1][3]. Group 1: Financial Fraud Cases - Numerous typical cases of financial fraud in listed companies over the past three to five years have been identified, including companies like Zijing Storage, Kangde Xin, Guizhou Bailing, and Yili Clean Energy, revealing complex relationships between actual controllers and financial directors, as well as chaotic corporate governance [3][4]. - In the case of Kangde Xin, the actual controller and financial director conspired to implement systematic financial fraud for seven years, while Zijing Storage's actual controller organized high-level executives to inflate revenue through fake contracts and falsified documents [4][5]. - The financial fraud methods commonly employed include inflating profits, manipulating costs, and creating fictitious assets, often involving collusion among key personnel [6][8]. Group 2: Penalties and Consequences - The penalties for financial fraud have been severe, with individuals facing both administrative and criminal consequences. For instance, Kangde Xin's actual controller received a 15-year prison sentence and a fine of 202 million RMB, while the financial director received a 13-year sentence and a fine of 10.15 million RMB [5][9]. - Companies involved in financial fraud face significant repercussions, such as ST Gaohong, which reported a cumulative litigation amount of 3.511 billion RMB, representing 427.64% of its latest audited net assets [9][10]. - The ongoing issues of financial fraud and deceptive practices are seen as major threats to the healthy development of China's capital market, undermining investor confidence and market fairness [9][10]. Group 3: Systemic Issues and Recommendations - The prevalence of financial fraud highlights systemic issues within corporate governance, including failures in internal controls and potential negligence by auditing firms, with some cases involving extensive collusion with third parties [10]. - Experts suggest that regulatory oversight of listed companies should be strengthened, with increased penalties for fraudulent activities and accountability for auditing firms and colluding third parties to maintain the integrity of the capital market [10].

中国经济网北京12月24日讯 贵州百灵企业集团制药股份有限公司（证券简称"ST百灵"，代码： 002424.SZ）复牌两跌停。该股今日收报5.08元，跌幅5.05%。12月23日该股收报5.35元，跌幅4.97%。 贵州百灵的上述行为涉嫌违反了《中华人民共和国证券法》(以下简称《证券法》)第七十八条第二 款的规定，构成《证券法》第一百九十七条第二款所述的违法情形。 公司股票自2025年12月22日（星期一）开市起停牌一天，并于2025年12月23日（星期二）开市起复 牌。公司股票在2025年12月23日（星期二）开市起被实施其他风险警示，公司股票简称由"贵州百灵"变 更为"ST百灵"；股票代码不变，仍为"002424"；股票交易日涨跌幅限制5%。 贵州百灵12月20日发布关于公司及相关当事人收到《行政处罚事先告知书》的公告。 公司于2024年11月8日收到中国证监会下发的《立案告知书》（编号：证监立案字0312024002 号），因公司涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》 等法律法规，中国证监会决定对公司立案。 根据贵州百灵违法行为的事实，性质，情节与社会危害程度，依 ...

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月20日，贵州百灵企业集团制药股份有限公司发布《关于公司及相关当事人收到<行政处罚事 先告知书>的公告》。该公告披露，因贵州百灵披露的相关年报存在虚假记载，贵州证监局决定对贵州 百灵给予行政处罚。 陈宇霞律师提醒，凡在2020年4月30日至2024年11月8日之间买入贵州百灵股票，且在2024年11月9 日之后继续持有或卖出亏损的投资者，均有权向贵州百灵索赔损失。（具体索赔条件以法院认定的为 准）（ST百灵维权入口） 违法事实： 中国证监会贵州监管局经调查认定，贵州百灵存在如下违法事实： 贵州百灵在财务核算时未执行 《企业会计准则—基本准则》 第九条的规定， 未以权责发生制为核算基 础， 按收入成本费用配比原则计提销售费用。贵州百灵2019年少计销售费用35，012.49万元，多计利润 35，012.49万元，占当期报告记载利润总额（绝对值）的95.73%；2020年少计销售费用24 ...

图源：文轩图库 半年时间，两度被戴帽，上市十余年之久的贵州百灵，这一次因虚增6个亿被罚，再度失信于股民。 公开信息显示，贵州百灵企业集团制药股份有限公司（以下简称：贵州百灵）前身为1999年成立的贵州省安顺地区制药厂，是一家以苗药研发、生产、销 售于一体的医药公司。 2010年，成功登陆深交所，被称为"中国苗药第一股"，目前已发展成为国内最大的苗药研制生产企业。 巅峰期的贵州百灵在资本市场的市值一度达到531亿，然而，截至目前市值仅为78.68亿元，跌幅超过85%。 半年内摘帽又戴帽 伤透股民的心 12月19日晚间，实现连涨3天的贵州百灵突然发布公告称，公司及相关当事人已收到贵州证监局送达的《行政处罚事先告知书》。经查，公司在2019年至 2023年期间存在财务造假行为，具体表现为： 2019年少计销售费用3.5亿元，相应多计利润3.5亿元，占当期报告记载利润总额（绝对值）的95.73%；2020年少计销售费用2.4亿元，多计利润2.4亿元， 占比达115.35%；2021年少计销售费用6379.16万元，多计利润6379.16万元，占比45.04%；2023年则多计销售费用4.59亿元，少计利润4.59亿元 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月20日，贵州百灵企业集团制药股份有限公司（以下简称"贵州百灵"或"公司"）发布公告称， 公司及相关责任人收到贵州证监局下发的《行政处罚事先告知书》（黔处罚字[2025]1号-11号）。据处 罚内容，其因2019-2021年虚增利润及2023年虚减利润致四年年报虚假记载，公司被警告并罚款1000万 元，11名相关责任人合计罚款1560万元，公司股票被实施其他风险警示，不触及重大违法强制退市。上 海市信本律师事务所赵敬国律师（执业证号：13101200410820485）提示，（1）于2024年1月31日-2024 年4月29日期间买入且有持仓，无论在2024年4月30日及之后是否卖出；（2）于2020年4月30日-2024年4 月29日期间买入且有持仓，无论在2024年4月30日及之后是否卖出的受损投资者，或可通过"新浪股民维 权平台 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 具体而言，公司未遵循收入与成本费用配比的原则，在财务核算中未能将实际发生的销售费用在当期及 时、足额确认。简单来说，就是通过故意推迟确认、或少计与当期收入相关的市场推广、渠道维护等销 售费用，将这些本应立刻体现在利润表中的支出"隐藏"或"转移"，从而人为做高当期利润。 【文/王力 编辑/周远方】 12月19日晚间，一则来自贵州证监局的《行政处罚事先告知书》，揭开了这家曾被誉为"苗药第一股"的 上市药企长达四年的财务造假真相。贵州百灵（002424.SZ）因在2019年至2021年及2023年年报中存在 虚假记载，被监管机构处以1000万元顶格罚款，公司股票将被实施其他风险警示，简称由"贵州百灵"变 更为"ST百灵（维权）"。 这家以银丹心脑通软胶囊、咳速停糖浆等产品闻名的苗药龙头，曾在2017年将其实际控制人姜伟家族推 上贵州首富的宝座，巅峰时期身家高达165亿元。如今，姜伟不仅面临500万元顶格罚款，还将被采取10 年证券市场禁入措施。与此同时，包括总经理牛民在内的10名责任人被处以合计1560万元罚款。 经查实，贵州百灵通过不当核算销售费用的方式，在201 ...

Core Viewpoint - Guizhou Bailing has been heavily penalized for financial fraud spanning from 2019 to 2023, with a total profit manipulation of 1.114 billion yuan, leading to significant fines for the company and its executives [1][2]. Financial Penalties and Fraud Details - Guizhou Bailing was fined 10 million yuan, while its actual controller and chairman Jiang Wei was fined 5 million yuan and banned from the securities market for 10 years [1]. - Other executives, including the former general manager and board members, received fines ranging from 350,000 to 2 million yuan, totaling 25.6 million yuan in penalties [1]. - The company manipulated profits by underreporting sales expenses and overstating profits over four years, with the most significant discrepancies occurring in 2019 and 2020 [1]. Company Performance - Guizhou Bailing reported revenues of 4.263 billion yuan in 2023, 3.825 billion yuan in 2024, and 2.102 billion yuan in the first three quarters of 2025, with year-on-year growth rates of 20.42%, -10.26%, and -24.28% respectively [2]. - The net profit figures were -412 million yuan in 2023, 37 million yuan in 2024, and 58 million yuan in the first three quarters of 2025, reflecting significant fluctuations in profitability [2]. Dispute with Huachuang Securities - A long-standing dispute with Huachuang Securities has escalated, originating from a 2018 rescue cooperation where Huachuang acquired a 11.54% stake in Guizhou Bailing for approximately 1.4 billion yuan [2][3]. - The relationship soured as Huachuang Securities began to exert control over the company, leading to allegations from Guizhou Bailing that Huachuang had transitioned from a financial investor to an actual controller [3]. - Legal actions have been initiated, with Guizhou Bailing accusing Huachuang of failing to sell its shares as agreed and manipulating stock prices through short selling [3][4]. Stock Market Impact - Guizhou Bailing's stock will be suspended for one day on December 22, 2023, and will resume trading under the new name "ST Bailing" on December 23, 2023, reflecting its status as a special treatment stock due to the financial penalties [1].